GoAI
Get started
Charmacy Pharmaceutical Co., Ltd. logo

Charmacy Pharmaceutical Co., Ltd.

2289.HK

HKSEHealthcareMedical - Distribution

Open in GoAI

Latest quote

HK$5.50

HK$0.00 · 0.00%

Aug 24, 11:21 AM HKTData delayed

2289.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and various healthcare items, along with associated advisory services. These are supplied to both wholesale distributors and retail pharmacies. Furthermore, Charmacy operates "Charmacy e-Medicine," its proprietary B2B digital platform, which enables clients to efficiently place orders, make inquiries, and process payments online. Founded in 1984, the firm maintains its headquarters in Shantou, PRC. It was formerly known as Chuangmei Pharmaceutical Co., Ltd. until its official renaming to Charmacy Pharmaceutical Co., Ltd. in July 2016.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Chuanglong Yao
Listed since
Dec 14, 2015
Employees
847

Market position

52-week range

Current HK$5.50

Open
HK$5.50
Previous close
HK$5.50
Volume
500
0.81× average
Average volume
614
Average daily volume
Market cap
594M HKD
Beta
-0.93
Market reference 1
50-day average
HK$6.437
-14.56% below average
200-day average
HK$6.2005
-11.30% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.04B CNY
P/E (TTM)
11.22×
P/B (TTM)
0.83×
P/S (TTM)
0.12×
EV / EBITDA
13.43×
Earnings yield
6.54%
Free cash flow yield
37.25%
Dividend yield
6.25%

Profitability & efficiency

Gross margin
7.76%
Operating margin
1.55%
Net margin
1.06%
Return on equity
7.50%
Return on assets
1.17%
Return on invested capital
1.80%

Financial health

Debt / equity
3.39×
Current ratio
1.09×
Altman Z-score
2.72
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends8%6%3%-0%Gross margin, FY2021: 6.17%Gross margin, FY2022: 6.43%Gross margin, FY2023: 6.65%Gross margin, FY2024: 7.32%Gross margin, FY2025: 7.66%Operating margin, FY2021: 0.85%Operating margin, FY2022: 2.91%Operating margin, FY2023: 1.50%Operating margin, FY2024: 1.65%Operating margin, FY2025: 1.55%Net margin, FY2021: 0.61%Net margin, FY2022: 2.17%Net margin, FY2023: 1.17%Net margin, FY2024: 1.20%Net margin, FY2025: 1.06%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 6.17%. Gross margin FY2022 6.43%. Gross margin FY2023 6.65%. Gross margin FY2024 7.32%. Gross margin FY2025 7.66%. Operating margin FY2021 0.85%. Operating margin FY2022 2.91%. Operating margin FY2023 1.50%. Operating margin FY2024 1.65%. Operating margin FY2025 1.55%. Net margin FY2021 0.61%. Net margin FY2022 2.17%. Net margin FY2023 1.17%. Net margin FY2024 1.20%. Net margin FY2025 1.06%.

Income trends

Revenue

4.38B CNY-1.15%

Operating income

68.1M CNY-7.03%

Net income

46.27M CNY-13.16%
Income trends across reported periods4.88B CNY3.11B CNY1.35B CNY−418.08M CNYRevenue, FY2021: 3.79B CNYRevenue, FY2022: 4.18B CNYRevenue, FY2023: 4.4B CNYRevenue, FY2024: 4.44B CNYRevenue, FY2025: 4.38B CNYOperating income, FY2021: 32.39M CNYOperating income, FY2022: 121.52M CNYOperating income, FY2023: 66.19M CNYOperating income, FY2024: 73.25M CNYOperating income, FY2025: 68.1M CNYNet income, FY2021: 23.15M CNYNet income, FY2022: 90.47M CNYNet income, FY2023: 51.34M CNYNet income, FY2024: 53.28M CNYNet income, FY2025: 46.27M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.79B CNY. Revenue FY2022 4.18B CNY. Revenue FY2023 4.4B CNY. Revenue FY2024 4.44B CNY. Revenue FY2025 4.38B CNY. Operating income FY2021 32.39M CNY. Operating income FY2022 121.52M CNY. Operating income FY2023 66.19M CNY. Operating income FY2024 73.25M CNY. Operating income FY2025 68.1M CNY. Net income FY2021 23.15M CNY. Net income FY2022 90.47M CNY. Net income FY2023 51.34M CNY. Net income FY2024 53.28M CNY. Net income FY2025 46.27M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue4.38B CNY4.44B CNY4.4B CNY4.18B CNY3.79B CNY
Cost of goods sold4.05B CNY4.11B CNY4.11B CNY3.91B CNY3.56B CNY
Gross profit336.01M CNY324.76M CNY292.74M CNY268.61M CNY234.12M CNY
Selling, general, and administrative194.92M CNY33.97M CNY170.8M CNY162.57M CNY151.56M CNY
Operating expenses267.91M CNY251.52M CNY226.55M CNY147.09M CNY201.73M CNY
Interest income2.14M CNY3.98M CNY4.3M CNY4.6M CNY3.8M CNY
Interest expense61.61M CNY60.65M CNY40.79M CNY35.07M CNY41.52M CNY
Depreciation and amortization20.6M CNY20.5M CNY28.71M CNY27.54M CNY33.06M CNY
Operating income68.1M CNY73.25M CNY66.19M CNY121.52M CNY32.39M CNY
Net income46.27M CNY53.28M CNY51.34M CNY90.47M CNY23.15M CNY

Company facts updated Aug 25, 2026.

Earnings

Latest EPS result
0.26

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.80.50.2-0.09Q2 '21Q4 '21Q3 '22Q2 '23Q2 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 0.289, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -0.032, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 31, 2022: actual 0.224, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 1, 2023: actual 0.736, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual 0.264, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 29, 2024: actual 0.256, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual 0.266, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 0.261, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.03B4.02B3.01B2BQ2 '21No estimateQ4 '21No estimateQ3 '22MissQ2 '23MissQ2 '23No estimateQ1 '24MissQ3 '24No estimateQ1 '25No estimate
Q2 2021, reported Jun 30, 2021: actual 2.39B HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 2.2B HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 31, 2022: actual 2.21B HKD, estimate 4.82B HKD, surprise -54.17%, Miss. Q2 2023, reported Apr 1, 2023: actual 2.61B HKD, estimate 4.82B HKD, surprise -45.93%, Miss. Q2 2023, reported Jun 30, 2023: actual 2.45B HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 29, 2024: actual 2.36B HKD, estimate 4.82B HKD, surprise -50.98%, Miss. Q3 2024, reported Aug 29, 2024: actual 2.52B HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 2.22B HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.489

2025 complete year+123.7% since 2020

2026 partial: HK$0.3435

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend May 27, 2026

HK$0.3435

Annual

Record May 29, 2026 · Payment Jun 25, 2026

Dividend

Ex-dividend May 26, 2025

HK$0.489

Annual

Record May 27, 2025 · Payment Jul 11, 2025

Dividend

Ex-dividend May 22, 2024

HK$0.3298

Annual

Record May 23, 2024 · Payment Jul 10, 2024

Dividend

Ex-dividend Jun 29, 2023

HK$0.4989

Annual

Record Jun 30, 2023 · Payment Jul 31, 2023

Dividend

Ex-dividend Jun 2, 2021

HK$0.2421

Annual

Record Jun 3, 2021 · Payment Jul 15, 2021

Dividend

Ex-dividend May 27, 2020

HK$0.2185

Annual

Record May 28, 2020 · Payment Jul 10, 2020

2289.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$202.2

+2.28%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.34

-0.26%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$223

+0.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$51.10

+5.14%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.46

+1.29%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.55

+0.05%

Continue in GoAI

Research 2289.HK

research.disclaimer